Jose Carmona
Direttore Finanziario/CFO presso ADC THERAPEUTICS SA
Patrimonio netto: 723 351 $ in data 30/04/2024
Posizioni attive di Jose Carmona
Società | Posizione | Inizio | Fine |
---|---|---|---|
ADC THERAPEUTICS SA | Direttore Finanziario/CFO | 19/12/2022 | - |
HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Jose Carmona
Precedenti posizioni note di Jose Carmona
Società | Posizione | Inizio | Fine |
---|---|---|---|
RUBIUS THERAPEUTICS | Comptroller/Controller/Auditor | 01/10/2020 | 15/11/2022 |
Direttore Finanziario/CFO | 01/10/2020 | 15/11/2022 | |
RADIUS HEALTH, INC. | Comptroller/Controller/Auditor | 15/05/2017 | - |
Direttore Finanziario/CFO | 15/05/2017 | 24/09/2020 | |
Treasurer | 15/05/2017 | 24/09/2020 | |
INNOCOLL HOLDINGS PLC | Direttore Finanziario/CFO | 01/09/2015 | 01/05/2017 |
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | Direttore Finanziario/CFO | 01/09/2015 | 01/01/2017 |
NOVARTIS AG | Corporate Officer/Principal | 01/01/2003 | 01/01/2015 |
Senda Biosciences, Inc.
Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | - | - |
Formazione di Jose Carmona
Universidad Técnica Federico Santa María | Undergraduate Degree |
Columbia Business School | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Irlanda | 3 |
Svizzera | 3 |
Posizioni
Director of Finance/CFO | 5 |
Comptroller/Controller/Auditor | 2 |
Director/Board Member | 2 |
Settori
Health Technology | 9 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
NOVARTIS AG | Health Technology |
ADC THERAPEUTICS SA | Health Technology |
Aziende private | 6 |
---|---|
Innocoll AG
Innocoll AG Pharmaceuticals: MajorHealth Technology Innocoll AG engages in the engineering, manufacture, sale of collagen-based products for post-surgical applications. Its pipeline products include bupivacaine-collagen bioresorbable implant, gentamicin-collagen topical matrix, and bioresorbable collagen film surgical adhesion barrier. The company was founded in December 1997 and is headquartered in Athlone, Ireland. | Health Technology |
Innocoll Holdings Plc
Innocoll Holdings Plc Pharmaceuticals: MajorHealth Technology Innocoll Holdings Plc operates as a pharmaceutical company. It focuses on the development and commercialization of pharmaceutical technologies to meet healthcare challenges. The firm's late-stage product pipeline is focused on addressing patient needs for postsurgical pain management. The company was founded in 1997 and is headquartered in Athlone, Ireland. | Health Technology |
Radius Health, Inc.
Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Health Technology |
Senda Biosciences, Inc.
Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Jose Carmona
- Esperienza